5-HT drugs and eating disorders

IDrugs

Volumn 1, Issue 4, 1998, Pages 456-470

  Kennett, G A ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0008670010     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (155)

1. Kuczmarski RJ, Flegan KM, Campbell SM, Johnson CL: Increasing prevalence of obesity among US adults: The national health and nutritional examination surveys, 1960 to 1991. JAMA (1994) 272:205-211.
2. Curzon G, Gibson L, Oluyomi AO: Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability. Trends in Pharmacological Sciences (1997) 18:21-25.
3. Levine LR, Pope HG, Enas GG, Wilson MG, Ballenger JC, Blinder BJ, et al.: Fluoxetine in the treatment of bulimia nervosa, a multicenter, placebo-controlled, double-blind trial. Arch Gen Psychiat (1992) 49:139-147.
4. Kennedy SH, Goldbloom DS: Current perspectives on drug therapies for anorexia nervosa and bulimia nervosa. Drugs (1991) 41:367-377.
5. Blundell J: Pharmacological approaches to appetite suppression. Trends in Pharmacological Sci (1991) 12:147-157.
6. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin G, Mylecharane EJ, Saxena PR, Humphrey PPA, (1994) International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Revs 46:157-203.
7. 7 receptor: Orphan found. Trends in Pharmacological Sciences (1997) 18:104-107.
8. Burns CM, Chu H, Rueter SM, Hutchinson LK, Canton H, Sanders-Bush E, Emeson RB: Regulation of serotonin-2C receptor G protein coupling by RNA editing. Nature (1997) 387:303-308.
9. Dourish CT, Hutson PH, Curzon G: Low doses of the putative serotonin agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) elicit feeding in the rat. Psychopharmacology (1985) 86:197-204.
10. Dourish CT, Hutson PH, Curzon G: Characteristics of feeding induced by the serotonin agonist, 8-hydroxy-2-di-n-propylamino)tetralin (8-OH-DPAT). Brain Res Bull (1985) 15:377-384.
11. Dourish CT, Clarke ML, Iversen SD: 8-OH-DPAT elicits feeding and not chewing: Evidence from liquid diet studies and a diet choice test. Psychopharmacology (1988) 95:185-188.
12. Wilkinson LO, Dourish CT: (1991) Serotonin and animal behaviour. In Serotonin receptor subtypes: Basic and clinical aspects, Wiley-Liss Inc, pp 147-210.
13. Fletcher PJ: 8-OH-DPAT elicits gnawing and eating of solid but not liquid, foods. Psychopharmacology (1987) 92:192-195.
14. Montgomery AMJ, Willner P, Muscat R: Behavioural specificity of 8-OH-DPAT-induced feeding. Psychopharmacology (1988) 94:110-114.
15. Dourish CT, Hutson PH, Curzon G: Parachlorophenylalanine prevents feeding induced by the serotonin agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). Psychopharmacology (1986) 89:467-471.
16. Muscat R, Montgomery AMJ, Willner P: Blockade of 8-OH-DPAT-induced feeding by dopamine antagonists. Psychopharmacology (1989) 99:402-408.
17. Shepherd JK, Rodgers RJ: 8-OH-DPAT specifically enhances feeding behaviour in mice: Evidence from behavioral competition. Psychopharmacology (1990) 101:408-413.
18. 1A receptor antagonist. Behav Brain Res (1996) 73:337-353.
19. Bendotti C, Samanin R: 8-Hydroxy-2-(di-n-propylamino) tetralin elicits feeding in free-feeding rats by acting on central serotonin neurons. Eur J Pharmacol (1986) 121:147-150.
20. 1A receptors. Eur J Pharmacol (1988) 150:361-366.
21. Fletcher PJ: Dopamine receptor blockade in nucleus accumbens, or caudate nucleus differentially affects feeding induced by 8-OH-DPAT injected into dorsal or median raphe. Brain Res (1991) 552:181-189.
22. Fletcher PJ, Davies M: The involvement of 5-hydroxytryptaminergic and dopaminergic mechanisms in the eating induced by buspirone, gepirone and ipsapirone. Br J Pharmacol (1990) 99:519-525.
23. 2B receptor agonist, causes hyperphagia and reduced grooming in rats. Neuropharmacology (1997) 36:233-239.
24. Amsterdam JD, Berwish N, Potter L, Rickels K: Open trial of gepirone in the treatment of major depressive disorder. Curr Therap Res 41:185-193.
25. Raykel RE: Long-term buspirone therapy for chronic anxiety: A multicentre international study to determine safety. Southern Med J (1990) 83:194-198.
26. Sheehan DV, Raj AB, Sheehan KH, Soto S: Is buspirone effective for panic disorder. J Clin Psychopharmacol (1990) 10:3-11.
27. Goa KL, Ward A: Buspirone: A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs (1986) 32:114-129.
28. Boyer WF, Feighner JP: A placebo-controlled double-blind multicenter trial of two doses of ipsapirone versus diazepam in generalised anxiety disorder. Int Clin Psychopharmacol (1993) 8:173-176.
29. 1A receptor agonist, in treatment-resistant depression. Int J Clin Psychopharmacol (1993) 8:167-172.
30. 1A receptor binding sites following chronic treatment with ipsapirone measured by quantitative autoradiography. Synapse 12:75-81.
31. 1A presynaptic, but not postsynaptic, receptor-mediated responses: Relationship to antidepressant-like action. Eur J Pharmacol (1987) 138:53-60.
32. Blier P, de Montigny, C: Current advances and trends in the treatment of depression. Trends in Pharmacological Sciences (1994) 15:220-226.
33. 1B/1D receptor ligands. Pharmacol Therap 62:385-405.
34. 1B agonists induce anorexia at a postsynaptic site. Eur J Pharmacol (1987) 141:429-435.
35. 1B receptors. Psychopharmacology (1988) 96:93-100.
36. 1 agonists TFMPP and RU 24969 on feeding following peripheral or medial hypothalamic injection. Brain Res (1992) 580:265-272.
37. 1B receptor ligands exist? Naunyn Schmiedebergs Arch Pharmacol (1989) 339:675-683.
38. Hutson PH, Donohoe TP, Curzon G: Infusion of the 5-hydroxytryptamine agonists RU 24969 and TFMPP into the paraventricular nucleus of the hypothalamus causes hypophagia. Psychopharmacology (1988) 95:550-552.
39. 1B) agonist and rotationally restricted phenolic analog of 5-methoxy-3-(1,2,5,6-tetrahydropyrid-4-yl) indole. J Med Chem (1990) 33:2087-2093.
40. 1B receptor agonist, CP-94,253. Drug Dev Res 26:241-250.
41. 1B) agonist that promotes satiety. Psychopharmacology (1997) 131:264-270.
42. 2C receptors in mediating fenfluramine-induced anorexia in rats. Brit J Pharmacol (1995) 114:373P.
43. Klodzinska A, Chojnacka-Wojcik E: Anorexia induced by m-trifluoromethylphenylpiperazine (TFMPP) in rats. Pol J Pharmacol (1990) 42:13-17.
44. 1B receptor. Brit J Pharmacol (1993) 110:1621-1629.
45. O'Neill MF, Fernandez AG, Palacios JM: GR-127935 blocks the locomotor and antidepressant-like effects of RU-24969 and the action of antidepressants in the mouse tail suspension test. Pharmacol Biochem Behav (1996) 53:535-539.
46. 1B receptor knockout - behavioral consequences. Behav Brain Res (1996) 73:305-312.
47. 1A receptors. Naunyn-Schmiedebergs Arch Pharmacol (1995) 352:583-584.
48. Palmer KJ, Spencer CM: Zoimitriptan. CNS Drugs (1997) 7:468-478.
49. 1C agonists. Psychopharmacology (1988) 96:101-103.
50. 2 receptors. Brit J Pharmacol (1988) 95:598-604.
51. 2 receptor mediation in quipazine anorexia. Psychopharmacology (1990) 100:115-118.
52. 2 antagonists in rats. Psychopharmacology (1988) 94:342-346.
53. 2 receptor agonists using the post-prandial satiety sequence in rats. Psychopharmacology (1994) 113:369-377.
54. 1 receptors elicits feeding in satiated rats. Psychopharmacology (1989) 97:54-58.
55. Fletcher, PJ, Burton, MJ: Microstructural analysis of the anorectic action of peripherally administered 5-HT. Pharmacol Biochem Behav (1986) 24:1133-1136.
56. Simansky KJ, Jakubow J, Sisk FC, Vaida AH, Eberle-Wang K: Peripheral serotonin is an incomplete signal for eliciting satiety in sham-feeding rats. Pharmacol Biochem Behav (1992) 43:847-854.
57. Simansky KJ: Serotonergic control of the organisation of feeding and satiety. Behav Brain Res (1996) 73:37-42.
58. 2 antagonist ritanserin on food intake, and on 5-HT-induced anorexia in the rat. Pharmacol Biochem Behav (1987) 26:333-340.
59. Edwards S, Stevens RG: Effects of xylamidine on peripheral 5-hydroxytryptamine-induced anorexia. Pharmacol Biochem Behav (1989) 34:717-720.
60. Samanin R, Mennini T, Ferraris A, Bendotti C, Borsini F, Garattini S: m-Chlorophenylpiperazine: A central serotonin agonist causing powerful anorexia in rats. Naunyn-Schmiedebergs Arch Pharmacol (1979) 308:159-163.
61. Clineschmidt BV, McGuffin JC, Pfeuger AB, Totaro JA: A 5-hydroxytryptamine-like mode of anorectic action for 6-chloro-2-(1-piperazinyl)-pyrazine (MK212). Brit J Pharmacol (1978) 62:579-589.
62. 2C receptors. Brit J Pharmacol (1988) 94:137-147.
63. 2 receptor agonist, MK 212, reduces food intake and increases resting but prevents the behavioral satiety sequence. Pharmacol Biochem Behav (1997) 56:41-46.
64. 1C receptors mediate 1-3(chlorophenyl)piperazine-induced hypophagia. Brit J Pharmacol (1991) 103:2016-2020.
65. 2C/2B receptor antagonist. Brit J Pharmacol (1994) 111:797-802.
66. 2 receptor subtypes: A family re-united? Trends in Pharmacol Sci (1995) 16:105-110
67. 2C receptor antagonist. Neuropharmacology (1997) 36:609-620.
68. 2C receptor gene inactivation. J Psychopharmacol (1996) 10 (Suppl 3):223.
69. Fletcher PJ: Increased food intake in satiated rats induced by the 5-HT antagonists methysergide, metergoline and ritanserin. Psychopharmacology (1988) 96:237-242.
70. 2C serotonin receptors. Nature (1995) 374:542-546.
71. Dourish CT, Vickers SP, Clifton PG, Tecott LH: Use of targeted gene deletion to examine the role of 5-HT mechanisms in feeding: Preclinical and clinical models in Psychopharmacology. Meribel (1997) Abstr 24.
72. 2B receptors in regulating seizure threshold in some rodent models of electrically and chemically-induced convulsions. Eur J Pharmacol (1997) (in press).
73. 2C receptor antagonist, SB-242084, on the rat satiety sequence. J Psychopharmacology (1997) 11 (Suppl 3):A47.
74. Gellai R: Gene-targeting studies of mammalian behaviour: Is it the mutation or the background genotype. Trends in Neuroscience (1996) 19:177-189.
75. 2C receptor antagonist Neuropharmacology (1997) 36:621-629.
76. 2C/2B receptor antagonist, after chronic treatment. Brit J Pharmacol (1995) 114:370P.
77. 2C receptor mutant mice. Am Soc Neurosci (1996) 22: Abstr 8112.
78. Walsh AES, Smith KA, Oldman AD, Williams C, Goodall EM, Cowen PJ: m-Chlorophenylpiperazine decreases food intake in a test meal. Psychopharmacology (1994) 116:120-122.
79. 2C receptor activation decreases appetite and body weight in obese subjects. Psychopharmacology (1997) (in press).
80. 1C receptors and their therapeutic relevance. Curr Opin Invest Drugs (1993) 2:317-362.
81. Cowen P, Clifford EM, Wiliams C, Walsh, AES, Fairburn CG: Why is dieting so difficult? Nature (1995) 376:557.
82. Haleem DJ: Functional specific supersensitivity of m-chlorophenylpiperazine-induced serotonergic neurotransmission in female compared to male rats. Life Sci 52:279-284.
83. 3 receptor antagonists in rats. Psychopharmacology (1995) 121:488-493.
84. Fletcher PJ, Davies M: Effects of 8-OH-DPAT, buspirone, and ICS 205-930 on feeding in a novel environment: Comparisons with chlordiazepoxide and FG 7142. Psychopharmacology (1990) 102:301-308.
85. Buchheit KH, Costall B, Engel G, Gunning SJ, Naylor RJ, Richardson BP: 5-hydroxytryptamine receptor antagonism by metodopramide and ICS 205930 in the guinea pig leads to enhancement of contractions of stomach muscle strips induced by electrical field stimulation, and facilitation of gastric empting in vivo. J Pharm Pharmacol (1985) 37:664-667.
86. 3 receptor agonists on rat food intake. Brit J Pharmacol (1992) 105:227P.
87. 4 receptor activation in the mouse. Eur J Pharmacol (1996) 308:181-186.
88. Silverstone T: Appetite suppressants: A review. Drugs (1992) 43:820-836.
89. McTavish D, Heel RC: Dexfenfluramine, a review of its pharmacological properties and therapeutic potential in obesity. Drugs (1992) 43:713-733.
90. Grignashi G, Neill JC, Petrini A, Garattini S, Samanin R: Feeding pattern studies suggest that d-fenfluramine and sertraline specificaly enhance the state of satiety in rats. Eur J Pharmacol (1992) 211:137-142.
91. 1 receptors Psychopharmacology (1989) 97:213-218.
92. Grignashi G, Samanin R: The role of 5-HT receptors in the effect of d-fenfluramine on feeding patterns in the rat. Eur J Pharmacol (1992) 212:287-289.
93. Raiteri M, Bonanno G, Vallebuona F: In vitro and in vivo effects of d-fenfluramine: No apparent relation between 5-hydroxytryptamine release and hypophagia. J Pharmacol Exp Therap (1995) 273:643-649.
94. Oluyomi AO, Gibson EL, Barnfield AMC, Curzon G: d-Fenfluramine and d-norfenfluramine hypophagias do not require increased hypothalamic 5-hydroxytryptamine release. Eur J Pharmacol (1994) 264:111-115.
95. Leibowitz SF, Weiss GF, Shor-Posner G: Hypothalamic serotonin: Pharmacological, biochemical and behavioural analyses of its feeding-suppressive action. Clin Neuropharmacol (1988) 11(Suppl 1): S51-S71.
96. Gibson EL, Kennedy AJ, Curzon G: d-Fenfluramine and d-norfenfluramine-induced hypophagia: Differential mechanisms and involvement of postsynaptic 5-HT receptors. Eur J Pharmacol (1993) 242:83-90
97. Borsini F, Bendotti C, Aleotti A, Samanin R, Garattini S: d-Fenfluramine and d-norfenfluramine reduce food intake by acting on different serotonergic mechanisms in the rat brain. Pharmacol Res Commun (1982) 14:71-678.
98. Tohyama I, Kameyama M, Kimura H: Quantitative morphometric analysis of two types of serotonin-immunoreactive nerve fibres differentially responding to p-chlorophenylalanine treatment in the rat brain. Neuroscience (1988) 26:71-977.
99. McCann UD, Yuan J, Ricaurte GA: Fenfluramine's appetite suppresion and serotonin neurotoxicity are separable. Eur J Pharmacol (1995) 283:R5-R7
100. Baker BJ, Duggan JP, Barber DJ, Booth DA: Effects of difenfluramine and xylamidine on gastric emptying of maintenance diet in freely-feeding rats. Eur J Pharmacol (1988) 150:137-142.
101. Samanin R, Neill JC, Grignashi G, Padura IM, Bizzi A, Garattini S: Role of 5-HT receptors in the effect of d-fenfluramine on gastric emptying and feeding behavior as examined in the runway test. Eur J Pharmacol (1991) 197:69-73.
102. Caccia S, Bizzi A, Cotro G, Fracasso C, Frittoli E, Mennini T, Garattini S: Anorectic activity of fluoxetine and norfluoxetine in rats: Relationship between brain concentrations and in vitro potencies on monoaminergic mechanisms. J Pharm Pharmacol (1992) 44:250-254.
103. 1B receptor mediates the effect of d-fenfluramine on eating caused by intra-hypothalamic injection of neuropeptide Y. Eur J Pharmacol (1995) 274:221-224.
104. Neill JC, Bendotti C, Samanin R: Studies on the role of 5-HT receptors in satiation, and the effect of d-fenfluramine in the runway test. Eur J Pharmacol (1990) 190:105-112.
105. 2c receptors. J Psychopharmacology (1997) 11(Suppl 3):48
106. Mennini T, Bizzi A, Caccia S, Codegoni A, Fracasso C, Frittoli E, Guiso G, Padura IM, Taddei C, Uslenghi A, Garattini S: Comparative studies on the anorectic activity of d-fenfluramine in mice, rats and guinea pigs. Naunyn-Schmiedebergs Arch Pharmacol (1991) 343:83-490.
107. Spedding M, Ouvry C, Milan M, Duhault J, Dacquet C, Wurtman R: Neural control of dieting. Nature (1996) 380:488.
108. Caccia S, Ballabio M, Giuso G, Rochetti M, Garattini S: Species differences in the kinetics and metabolism of fenfluramine Isomers. Arch Int Pharmacodyn (1982) 258:15-28.
109. Caccia S, Anelli M, Fracasso C, Frittoli E, Giorcelli P, Gobbi M, Taddei C, Garattini S, Mennini T: Anorectic and brain concentrations of d-fenfluramine in the marmoset: relationship to the in vivo and in vitro effects on serotonergic mechanisms. Naunyn-Schmiedebergs Arch Pharmacol (1993) 347:306-312.
110. Goodall EM, Cowen PJ, Franklin M, Silverstone T: Ritanserin attenuates anorectic, endocrine and thermic responses to d-fenfluramine in human volunteers. Psychopharmacology (1993) 112:461-466.
111. Garattini S, Mennini T, Bendotti C, Invernizzi R, Samanin R: Neurochemical mechanism of action of drugs which modify feeding via the serotonergic system. Appetite (1986) 7:15-38.
112. Bettini E, Ceci A, Spinelli R, Samanin R: Neuroleptic-like effects of the I-isomer of fenfluramine on striatal dopamine release in freely moving rats. Biochem Pharmacol (1987) 36:2387-2391.
113. Invernizzi R, Bertorelli R, Consolo S, Garattini S, Samanin R: Effects of the I-isomer of fenfluramine on dopamine mechanisms in rat brain: Further studies. Eur J Pharmacol (1989) 120:9-13.
114. Kleven MS, Schuster CR, Seiden LS: Effect of depletion of brain serotonin by repeated fenfluramine on neurochemical and anorectic effects of acute fenfluramine. J Pharmacol, Exp Therap (1988) 246:822-828.
115. Appel NM, Mitchell WMM, Contrera JF, De Souza EB: Effects of high dose fenfluramine treatment on monoamine uptake sites in the brain: Assessment using quantitative autoradiography. Synapse (1990) 6:33-44.
116. Westphalen RI, Dodd PR: New evidence for a loss of serotonergic nerve terminals in rats treated with difenfluramine. Pharmacol and Toxicol (1993) 72:249-255.
117. Steranska LR, Sanders-Bush E: Long-term effects of fenfluramine on central serotonergic mechanisms. Neuropharmacology (1979) 18:895-903
118. Appel NM, Contrera JF, De Souza EB: Fenfluramine selectively and differentially decreases the density of serotonergic nerve terminals in rat brain: Evidence from immunocytochemical studies. J Pharmacol Exp Therap (1989) 249:928-943.
119. Molliver DC, Molliver ME: Anatomical evidence for a neurotoxic effect of (+/-)-fenfluramine upon serotonergic projections in the rat. Brain Res (1990) 511:165-168.
120. Rose S, Hunt S, Collins Hindmarsh JG, Jenner P: Repeated administration of escalating doses of dexfenfluramine does not produce morphological evidence for neurotoxicity in the cortex of the rat. Neurodegeneration (1996) 5:145-152.
121. McGuirk JM, Muscat R, Willner P: Effects of chronically administered fluoxetine and fenfluramine on food intake, body weight, and the behavioral satiety sequence. Psychopharmacology (1992) 106:401-407.
122. Grignashi G, Samanin R: Role of serotonin and catecholamines in brain in the feeding suppressant effect of fluoxetine. Neuropharmacology (1992) 31:445-449.
123. Lightowler SL, Wood MD, Brown T, Glen A, Blackburn TP, Tulloch I, Kennett GA: An investigation of the mechanism responsible for fluoxetine-induced hypophagia in rats. Eur J Pharmacol (1996) 296:137-143.
124. Wong DT, Threlkeld PG, Robertson DW: Affinities of fluoxetine, its enantiomers, and other inhibitors of serotonin uptake for subtypes of serotonin receptors. Neuropsychopharmacology (1991) 5:43-47.
125. 7 serotonin receptor subtype. J Biol Chem (1993) 268:18200-18204.
126. Wong DT, Reid LR, Threlkeld G: Suppresion of food intake In rats by fluoxetine: Comparison of enantiomers and effects of serotonin antagonists. Pharmacol Biochem Behav (1988) 31:475-479.
127. Lee MD, Clifton PG: Partial reversal of fluoxetine anorexia by the 5-HT antagonist, metergoline. Psychopharmacology (1992) 107:359-364.
128. Halford JCG, Blundell JE: Metergoline antagonizes fluoxetine-induced suppression of food intake, but not changes in the behavioral satiety sequence. Pharmacol Biochem Behav (1996) 54:745-751.
129. Dryden S, Frankish HM, Wang Q, Pickavance L, Williams G: The serotonergic agent fluoxetine reduces neuropeptide Y levels and neuropeptide Y secretion in the hypothalamus of lean and obese rats. Neuroscience (1996) 72:557-566.
130. Heilig M, Wahlstedt C, Ekman R, Widerlov E: Antidepressant-like drugs increase the concentration of neuropeptide Y (NPY)-like immunoreactivity in the rat brain. Eur J Pharmacol (1988) 147:465-469.
131. Bellman R, Sperk G, Effects of antidepressant drug treatment on levels of NPY, or prepro-NPY-mRNA in the rat brain. Neurochem Int (1993) 22:183-187.
132. Simansky KJ, Vaidya AH: Behavioral mechanisms for the anorectic action of the serotonin (5-HT) uptake inhibitor sertraline in rats: Comparison with directly acting 5-HT agonists. Brain Res Bull (1990) 25:953-960.
133. Nielsen JA, Chapin DS, Johnson JL, Torgersen LK: Sertraline, a serotonin-uptake inhibitor, reduces food intake and body weight in lean rats and genetically obese mice. Am J Clin Nutr (1992) 55:185S-188S.
134. Lucki I, Kreider MS, Simansky KJ: Reduction in feeding behavior by the serotonin uptake inhibitor sertraline. Psychopharmacology (1988) 96:289-295.
135. Simansky KJ, Lemieux J, Sisk PC: Sertraline and other serotonin (5-HT) uptake inhibitors potently reduce nocturnal free-feeding in rats. Soc Neurosci Abstr (1988) 14:614.
136. Grignashi G, Samanin R: Role of serotonin receptors in the effect of sertraline on feeding behavior. Psychopharmacology (1993) 110:203-208.
137. Fernstrom MH, Massoudi M, Kupfer DJ: Fluvoxamine and weight loss. Biological Psychiatry (1988) 24:948-949.
138. Rasmussen JGC, Johnson AM, Stewart B, Palmer KJ: Comparative effects of the selective serotonin uptake Inhibitors paroxetine and fluoxetine on food intake in rats and effect of paroxetine on body weight in depressed patients. J Psychopharmacol (1990) 4:4.
139. Szkudlarek, J, Elsborg, L: Treatment of severe obesity with a highly selective serotonin reuptake inhibitor as a supplement to a low calorie diet. Int J Obes Rel Metab Disor (1993) 17:681-683.
140. Bouwer CD, Harvey BH: Phasic craving for carbohydrate observed with citalopram Int Clin Psychopharmacol (1996) 11:273-278.
141. 1A receptors. Brit J Pharmacol (1997) (in press).
142. Griffiths J, Brynes AE, Frost G, Bloom SR, Finer N, Jones SP, Romanec FM: Sibutramine in ther treatment of overweight non-insulin dependent diabetics. Int J Obesity (1995) 19 (Suppl 2):41.
143. Jackson HC, Bearham MC, Mazurkiewicz SE, Heal DJ, Buckett WR: Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and NA reuptake inhibitor sibutramine in the rat. Brit J Pharmacol (1996) 117:168P
144. Stricker-Krongrad A, Souquet A-M, Jackson HC, Burlet C: Effect of various monoamine receptor antagonists on the decrease in food intake induced by sibutramine. Brit J Pharmacol (1996) 117:167P.
145. Jackson HC, Hutchins LJ, Mazurkiewicz SE, Heal DJ, Buckett WR: Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. Brit J Pharmacol (1996) 117:323P.
146. Liu Y-L, Kashani SMZ, Heal DJ, Stock MJ: Effect of sibutramine on tissue glucose utilization in the rat. Brit J Pharmacol (1996) 117:324P.
147. Jones RB, Jackson HC, Cheetham SC, Anthony DM, Sills S, Heal DJ, Buckett WR: Chronic administration of sibutramine reduces plasma glucose levels in obese hyperglycaemic (ob/ob) mice. Brit J Pharmacol (1997) 120:352P.
148. Chiodo J, Latimer PR: Hunger perceptions and satiety responses among normal weight bulimics and normals to a high calorie, carbohydrate-rich food. Psychol Med (1986) 16:343-349.
149. Kaye WH, Ebert MH, Gwirtsman HE, Weiss SR: Differences in brain serotonergic metabolism between non-bulimic and bulimic patients with anorexia nervosa. Am J Psychiat (1984) 141:1598-1601.
150. Jimerson DC, Lesem MD, Kaye WH, Brewerton TD: Low dopamine and serotonin metabolite concentrations in cerebral spinal fluid from bulimic patients with frequent binge episodes. Arch Gen Psychiat (1992) 49:132-138.
151. Levitan RD, Kaplan AS, Joffe RT, Levitt AJ, Brown GM: Hormonal and subjective responses to intravenous metachlorophenylpiperazine in bulimia nervosa. Arch Gen Psychiat (1997) 54:521-527.
152. Jimerson DC, Wolfe BE, Metzer ED, Finkelstein DM, Cooper TB, Levine JM: Decreased serotonin function in bulimia nervosa. Arch Gen Psychiat (1997) 54:529-534.
153. Robinson PH, Checkley SA, Russell GFM: Suppression of eating by fenfluramine in patients with bulimia nervosa. Brit J Psychiat (1985) 146:169-176.
154. Blouin AG, Blouin JH, Perez EL, Bushnik T, Zuro C: Treatment of bulimia with fenfluramine and desipramine. J Clin Psychopharmacol (1988) 8:261-269.
155. Goldbloom DS, Kennedy SH: Adverse interaction of fluoxetine and cyproheptadine in two patients with bulimia nervosa. J Clin Psychiat (1991) 52:261-262.